MedPath

Oxazepam

Generic Name
Oxazepam
Brand Names
Oxpam
Drug Type
Small Molecule
Chemical Formula
C15H11ClN2O2
CAS Number
604-75-1
Unique Ingredient Identifier
6GOW6DWN2A
Background

Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine lorazepam, is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both diazepam and temazepam and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.

Indication

Oxazepam is indicated for the management of anxiety disorders and for the short-term relief of symptoms of anxiety. It may also be used in the management of alcohol withdrawal symptoms.

Associated Conditions
Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Songha® Night
Drug: Placebo
First Posted Date
2014-10-24
Last Posted Date
2014-10-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02273453

Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome

Phase 4
Completed
Conditions
Alcohol Withdrawal Syndrome
Alcohol Dependence
Interventions
First Posted Date
2014-03-18
Last Posted Date
2014-03-18
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
127
Registration Number
NCT02090504
Locations
🇮🇹

"G. Fontana" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna, Bologna, BO, Italy

🇮🇹

Catholic University of Rome, Rome, Rm, Italy

🇦🇹

University of Wien, Wien, AT, Austria

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

Not Applicable
Completed
Conditions
Cocaine Dependence
Cocaine Addiction
Interventions
First Posted Date
2007-12-05
Last Posted Date
2008-12-31
Lead Sponsor
Embera NeuroTherapeutics, Inc.
Target Recruit Count
45
Registration Number
NCT00567814
Locations
🇺🇸

Department of Psychiatry, Psychopharmacology Research Clinic, Shreveport, Louisiana, United States

The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2008-08-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
8
Registration Number
NCT00000661
Locations
🇺🇸

Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath